Enzolytics, Inc. (OTCPK: ENZC)
Health Care · Biotechnology · US
$0.00
+20.00% today · -7.7% 1Y
Enzolytics, Inc. (OTCPK: ENZC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.90M and employs 1 people.
Over the last twelve months the share price has lost 7.7%, trading between 0.00 and 0.00.
Tweenvest scores Enzolytics, Inc. across four factors: quality 5/100, value 53/100. Its strongest factor is value.
ENZC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.90M
- Revenue (TTM)
- $46.59K
- P/E
- —
- EPS
- -4.76
- Dividend yield
- —
- Beta (5Y)
- 0.51
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 4.83B
- Employees
- 1
- Next earnings
- —
About Enzolytics, Inc.
Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary cell line, specifically engineered to produce human monoclonal antibodies that effectively target and neutralize the human immunodeficiency virus (HIV).
- ISIN
- US2941121079
- Listed since
- Apr 8, 2009
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.